HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

Abstract
Imatinib mesylate, a selective inhibitor of the Abl tyrosine kinase, is effective as a single-agent therapy for chronic myelogenous leukemia. However, resistance has been reported, particularly in patients with advanced-stage disease. Mutations within the Abl kinase domain are a major cause of resistance, demonstrating that Bcr-Abl remains a critical drug target. Recently, a novel pyrido[2,3-d]pyrimidine derivative, PD180970, has been shown to potently inhibit Bcr-Abl and induce apoptosis in Bcr-Abl-expressing leukemic cells. We analyzed the inhibitory activity of PD180970 against Abl kinase domain mutations and cells expressing clinically relevant mutations. Our data indicate that PD180970 is active against several Bcr-Abl mutations that are resistant to imatinib and support the notion that developing additional Abl kinase inhibitors would be useful as a treatment strategy for chronic myelogenous leukemia.
AuthorsPaul La Rosée, Amie S Corbin, Eric P Stoffregen, Michael W Deininger, Brian J Druker
JournalCancer research (Cancer Res) Vol. 62 Issue 24 Pg. 7149-53 (Dec 15 2002) ISSN: 0008-5472 [Print] United States
PMID12499247 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Protein Isoforms
  • Pyridones
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • PD 180970
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Benzamides
  • Cell Line
  • Drug Resistance, Neoplasm (genetics)
  • Enzyme Inhibitors (pharmacology)
  • Fusion Proteins, bcr-abl
  • Hematopoietic Stem Cells (enzymology, physiology)
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, enzymology, genetics)
  • Mice
  • Mutagenesis, Site-Directed
  • Piperazines (pharmacology)
  • Protein Isoforms
  • Protein Structure, Tertiary
  • Protein-Tyrosine Kinases (antagonists & inhibitors, genetics)
  • Pyridones (pharmacology)
  • Pyrimidines (pharmacology)
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: